Skip to main content

Primary Biliary Cholangitis clinical trials at University of California Health

11 in progress, 6 open to eligible people

Showing trials for
  • Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

    “Volunteering for the GLISTEN trial could bring much-needed medical progress in PBC itch!”

    open to eligible people ages 18-80

    This is a 2-part study in PBC participants with cholestatic pruritus and will evaluate the efficacy, safety and impact on health-related quality of life of linerixibat compared with placebo.

    at UCSF

  • Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

    “Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”

    open to eligible people ages 18-80

    The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects with Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

    at UC Davis

  • IDEAL: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)

    open to eligible people ages 18-75

    To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)

    at UC Davis

  • Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis

    open to eligible people ages 18-75

    Saroglitazar Magnesium 1 mg and 2 mg tablets for treatment of subjects with Primary Biliary Cholangitis (PBC)

    at UC Davis

  • Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

    open to eligible people ages 18-75

    An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

    at UC Davis

  • Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

    open to eligible people ages 18-75

    To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.

    at UC Davis UCSF

  • Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

    Sorry, in progress, not accepting new patients

    The primary objective of this study is to evaluate the effect of setanaxib on alkaline phosphatase (ALP) at Week 24 in participants with PBC and with elevated liver stiffness and intolerance or inadequate response to ursodeoxycholic acid (UDCA).

    at UC Davis

  • OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

    “Primary Biliary Cholangitis may be rare. But we’re working together.”

    Sorry, in progress, not accepting new patients

    Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (OCA) in participants with Primary Biliary Cholangitis (PBC).

    at UC Davis

  • Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

    Sorry, in progress, not accepting new patients

    The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid (which is a medication used in the management and treatment of cholestatic liver disease). PBC is a slowly progressive disease characterized by damage of the bile ducts in the liver, leading to a buildup of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms. Many patients with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not done. This study has two main parts; the first part will compare a daily dose of elafibranor (the study drug) to a daily dose of placebo (a dummy treatment), and will last between a minimum of one year and a maximum of two years. In the second part, all participants will receive elafibranor, for a period between 4-5 years. The main aim of this study is to determine if elafibranor is better than placebo at decreasing the levels of a specific blood test (alkaline phosphatase) that provides information about participant's disease. This study will also study the safety of long-term treatment with elafibranor, as well as the impact on symptoms such as pruritus and fatigue.

    at UC Davis

  • PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

    “Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”

    Sorry, in progress, not accepting new patients

    This study is a Phase 2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-104. The study consists of a 120 day primary study followed by a 20 month long-term safety and durability of response follow-up period.

    at UC Davis

  • 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis

    Sorry, in progress, not accepting new patients

    This is a 5-year, longitudinal, observational study of patients with PBC designed to specifically address important clinical questions that remain incompletely answered from registration trials. In addition to the study database, a bio specimen repository will also be included so that translational studies of genomics and biomarkers of response may be performed.

    at UC Davis

Our lead scientists for Primary Biliary Cholangitis research studies include .

Last updated: